National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
|Podcasts|October 20, 2020
Navigating Addiction Treatment in the Face of Difficulties
Author(s)John Calvin Chatlos, MD
How can clinicians help patients struggling with addiction, especially during this time when uncovering past traumas might feel impractical?
Advertisement
PSYCHPEARLS PODCAST
How can clinicians help patients struggling with addiction, especially during this time when uncovering past traumas might feel impractical?
Psychiatric Times interviews child and adolescent and addiction psychiatrist, John Calvin Chatlos, MD. Dr Chatlos is affiliated with Rutgers-Robert Wood Johnson Medical School, in New Brunswick, NJ, and medical director of the Wei Ji Point Ambulatory Withdrawal Management program and the Specialized Addiction Treatment Services outpatient program.
Advertisement
Related to this article
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
5